Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Contraception ; 91(5): 418-22, 2015 May.
Article in English | MEDLINE | ID: mdl-25645461

ABSTRACT

OBJECTIVE: Studies in mice suggest that cilostazol, an FDA-approved phosphodiesterase 3 (PDE3) inhibitor, might have a contraceptive effect within the approved dose range. We sought to evaluate the potential contraceptive effects of cilostazol in a nonhuman primate model. STUDY DESIGN: Adult female rhesus macaques were stimulated to develop multiple preovulatory follicles by administering human recombinant gonadotropins, and oocytes were collected by follicle aspiration 36 h after an ovulatory stimulus (human chorionic gonadotropin). Monkeys received no further treatment (controls) or the PDE3 inhibitor cilostazol at the maximum approved human dose of 100mg twice daily starting 6 days prior to follicle aspiration. Recovered oocytes were scored for meiotic stage [germinal vesicle (GV) intact, GV breakdown], and metaphase II stage oocytes were fertilized in vitro and observed for normal embryo development. RESULTS: Similar proportions of GV stage oocytes were recovered from control (27%±4%) and cilostazol (27%±9%)-treated females, and the proportion of embryos that developed into blastocysts was also similar for both groups (7%±5% control vs. 15%±8% cilostazol). CONCLUSION: Oral dosing of cilostazol tablets during controlled ovarian stimulation protocols did not prevent oocyte maturation or embryo development in macaques. IMPLICATIONS: Since administration of the maximum approved human dose of cilostazol (an FDA-approved PDE3 inhibitor) to macaques did not prevent oocyte maturation or fertilization, it is not likely that this dose would be contraceptive in women.


Subject(s)
Chorionic Gonadotropin/administration & dosage , Oocytes/drug effects , Oogenesis/drug effects , Phosphodiesterase 3 Inhibitors/administration & dosage , Tetrazoles/administration & dosage , Animals , Blastocyst/drug effects , Cilostazol , Female , Humans , Macaca mulatta , Meiosis , Mice , Models, Animal , Recombinant Proteins/administration & dosage
2.
Dev Biol ; 371(2): 146-55, 2012 Nov 15.
Article in English | MEDLINE | ID: mdl-22935618

ABSTRACT

Inactivation of one X chromosome in female mammals (XX) compensates for the reduced dosage of X-linked gene expression in males (XY). However, the inner cell mass (ICM) of mouse preimplantation blastocysts and their in vitro counterparts, pluripotent embryonic stem cells (ESCs), initially maintain two active X chromosomes (XaXa). Random X chromosome inactivation (XCI) takes place in the ICM lineage after implantation or upon differentiation of ESCs, resulting in mosaic tissues composed of two cell types carrying either maternal or paternal active X chromosomes. While the status of XCI in human embryos and ICMs remains unknown, majority of human female ESCs show non-random XCI. We demonstrate here that rhesus monkey ESCs also display monoallelic expression and methylation of X-linked genes in agreement with non-random XCI. However, XIST and other X-linked genes were expressed from both chromosomes in isolated female monkey ICMs indicating that ex vivo pluripotent cells retain XaXa. Intriguingly, the trophectoderm (TE) in preimplantation monkey blastocysts also expressed X-linked genes from both alleles suggesting that, unlike the mouse, primate TE lineage does not support imprinted paternal XCI. Our results provide insights into the species-specific nature of XCI in the primate system and reveal fundamental epigenetic differences between in vitro and ex vivo primate pluripotent cells.


Subject(s)
Embryo, Mammalian/metabolism , Pluripotent Stem Cells/metabolism , X Chromosome Inactivation , X Chromosome/genetics , Animals , Blastocyst/metabolism , Cell Lineage , Embryonic Stem Cells/cytology , Embryonic Stem Cells/metabolism , Female , Genes, X-Linked , Genomic Imprinting , Macaca mulatta , Male
3.
Am J Primatol ; 69(8): 917-29, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17358011

ABSTRACT

The vervet monkey was evaluated as a primate model for use in assisted reproductive technologies (ARTs). Eight adult female vervets were hormonally monitored for their potential use as egg donors and those six females displaying regular menstrual cycles were subjected to controlled ovarian stimulation with recombinant human gonadotropins. Three animals failed to respond while laparoscopic follicular aspiration was performed on the other three females at 27-30 h post-human chorionic gonadotropin administration. A total of 62, 40, and 18 oocytes was recovered from these three animals of which 30, 20, and 4, respectively, matured to the metaphase II stage and were subsequently inseminated using intracytoplasmic sperm injection. An average of 40+/-15% (SEM) of the inseminated oocytes were fertilized based on pronucleus formation and timely cleavage. One embryo from each of the two stimulated females developed into expanded blastocysts. Two adult male vervets were assessed as sperm donors. Neither adjusted well to the restraint and collection procedure required for penile electroejaculation. Samples collected via rectal electroejaculation were very low in sperm motility and concentration; however, cauda epididymal aspirations from one male yielded an adequate concentration of motile sperm. These results emphasize the need to establish species-specific ovarian stimulation protocols and semen collection techniques if vervets are to be considered for basic and applied (ARTs) research on primate gametes or embryos.


Subject(s)
Cercopithecinae , Models, Animal , Sperm Injections, Intracytoplasmic , Animals , Blastocyst/cytology , Ejaculation , Embryo Transfer , Embryonic Development , Female , Male , Ovarian Follicle/diagnostic imaging , Ovulation Induction , Species Specificity , Sperm Motility , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...